drugset / Trial / NCT02719613
Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab
NaSingle-groupOpen-labelSupportive care
Summary
The purpose of this study is to continue to provide elotuzumab and/or other study drugs to participants who have participated on a prior protocol investigating elotuzumab who are not able to receive commercial drug supply.
Timeline
- Start
- 2016-07-15
- Primary completion
- 2026-02-23
- Completion
- 2026-02-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Elotuzumab | Monoclonal antibody | — | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | — | Intravenous |
| Background | Bortezomib | Small molecule | — | Intravenous |
| Background | Dexamethasone | Small molecule | — | Oral |
| Background | Lenalidomide | Other / unclassified | — | Oral |
| Background | Pomalidomide | Other / unclassified | — | Oral |